{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:39:15Z","timestamp":1791581955145,"version":"4.3.4"},"reference-count":44,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ataxia telangiectasia and Rad3\u2010related (ATR) inhibition with berzosertib potentiates the efficacy of irinotecan in preclinical models. The authors hypothesize that this combination is well tolerated, modulates the DNA damage response to irinotecan, and is associated with clinical activity in advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this phase 1 study (NCT02595931), berzosertib 60\u2013270 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      was administered with irinotecan 180 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      every 2 weeks in a 4\u2010week cycle. The primary end point was determination of the maximum tolerated dose and recommended phase 2 dose (RP2D). Antitumor activity, pharmacokinetics, and pharmacodynamics were secondary end points.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty\u2010three patients were enrolled, the majority with colorectal cancer (49%) or pancreatic cancer (21%). Median number of prior lines of therapy was four (range, 2\u20137). Two dose\u2010limiting toxicities, both febrile neutropenia, occurred among 45 patients treated with berzosertib 270 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and irinotecan 180 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . The most common treatment\u2010related grade \u22653 toxicities were lymphopenia (30%), neutropenia (29%), and anemia (25%). Two partial responses occurred in patients with pancreatic cancer and ataxia telangiectasia mutated (ATM) alterations: 32% decrease in an ATM E11828\/ATM K1109* tumor lasting 15.8 months and 57% decrease in an ATM R3008H\/germline ATM R1882* tumor lasting 13.6 months. Induction of DNA damage markers \u03b3H2AX and pNBS1 was observed in one tumor biopsy obtained post berzosertib and irinotecan combination treatment compared with post irinotecan alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Berzosertib 270 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and irinotecan 180 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      was the RP2D. The combination is associated with manageable side effects and promising disease activity in ATM mutant solid tumors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70157","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:51:30Z","timestamp":1761763890000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase 1 clinical trial of the ataxia telangiectasia and Rad3\u2010related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)"],"prefix":"10.1002","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-523X","authenticated-orcid":false,"given":"Liza C.","family":"Villaruz","sequence":"first","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Department of Medicine School of Medicine University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxiao","family":"Jin","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Department of Medicine School of Medicine University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"},{"name":"Department of Biostatistics School of Public Health University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Department of Medicine School of Medicine University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Luke","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Department of Medicine School of Medicine University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Rhee","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiama N.","family":"Waqar","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-3951","authenticated-orcid":false,"given":"James","family":"Cleary","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwakar","family":"Davar","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Department of Medicine School of Medicine University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-3762","authenticated-orcid":false,"given":"Timothy F.","family":"Burns","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Department of Medicine School of Medicine University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Verma","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center  Sacramento California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Amin","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Appleman","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"},{"name":"Division of Hematology\/Oncology Department of Medicine School of Medicine University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen K.","family":"Ciombor","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-2435","authenticated-orcid":false,"given":"Elizabeth J.","family":"Davis","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center  Sacramento California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Claire","family":"Dees","sequence":"additional","affiliation":[{"name":"Division of Oncology Department of Medicine University of North Carolina  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Kim","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center  Sacramento California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Cardin","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Guo","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Christner","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-7459","authenticated-orcid":false,"given":"Joshua","family":"Deppas","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina M.","family":"Parise","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program UPMC Hillman Cancer Center  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Program in Oncology University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella S.","family":"Guerrouahen","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4393-5750","authenticated-orcid":false,"given":"Michael","family":"Suchko","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Contreras","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research Clinical Pharmacodynamics Biomarker Program Applied\/Developmental Research Directorate  Frederick Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine V.","family":"Ferry\u2010Galow","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research Clinical Pharmacodynamics Biomarker Program Applied\/Developmental Research Directorate  Frederick Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting\u2010Chia","family":"Chang","sequence":"additional","affiliation":[{"name":"Molecular Characterization Laboratory Frederick National Laboratory for Cancer Research  Frederick Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahanawaz","family":"Jiwani","sequence":"additional","affiliation":[{"name":"Molecular Characterization Laboratory Frederick National Laboratory for Cancer Research  Frederick Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Bakkenist","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology UPMC Hillman Cancer Center School of Medicine University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chu","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Cancer Canter  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis Investigational Drug Branch Cancer Therapy Evaluation Program National Cancer Institute  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Cancer Center at Johns Hopkins  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.03.002"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.12.001"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.573"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6247"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1977"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201013\u20103369"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02404"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2307\/2531693"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.08.037"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181ec3bf5"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1084"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.162"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2019.06.002"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201018\u20102523"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201021\u20100329"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35755"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.007"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1013157727506"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604530"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn020"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010021\u201001406\u2010w"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6915"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010021\u201001405\u2010x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010020\u201004184\u2010z"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010005\u20100166\u20105"},{"key":"e_1_2_9_27_1","volume-title":"Medical Genetics Summaries [Internet]","author":"Dean L","year":"2012"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.049"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10086"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00286"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201020\u20100418"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa121"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201022\u20101483"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5617"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.08.010"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac160"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30180\u20107"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00635"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4025"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3441"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010024\u201004745\u20106"},{"issue":"4","key":"e_1_2_9_44_1","first-page":"669","article-title":"Mechanisms of corticosteroid action on lymphocyte subpopulations. I. Redistribution of circulating T and b lymphocytes to the bone marrow","volume":"28","author":"Fauci AS","year":"1975","journal-title":"Immunology"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201023\u20102409"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T20:27:16Z","timestamp":1762201636000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":44,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/cncr.70157"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70157","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"2025-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70157"}}